中危前列腺癌标准剂量与剂量递增放疗的随机临床试验
NRG Oncology/RTOG 0126随机临床试验纳入1532例中危前列腺癌患者,比较79.2 Gy与70.2 Gy放疗。
要点
- 剂量递增至79.2 Gy未改善中危前列腺癌患者的总生存。
- 高剂量组生化失败率和远处转移率更低,挽救治疗使用率更低。
- 高剂量组晚期≥2级胃肠和泌尿生殖毒性反应显著增加。
核心结论
- 尽管剂量递增改善了生化控制率和远处转移率,但未改善总生存。
- 高剂量放疗导致更多晚期毒性反应,但挽救治疗使用率更低。
研究设计与样本
- NRG Oncology/RTOG 0126随机临床试验,2002年3月至2008年8月从104个北美放射治疗肿瘤学组机构随机纳入1532例患者。
- 纳入标准为cT1b-T2b期、Gleason评分2-6且PSA≥10且<20 ng/mL,或Gleason评分7且PSA<15 ng/mL。
- 患者接受三维适形放疗或调强放疗,随机分为79.2 Gy/44次或70.2 Gy/39次。
主要发现
- 中位随访8.4年(范围0.02-13.0),1499例患者可评估,中位年龄71岁(范围33-87),70%患者PSA<10 ng/mL,84% Gleason评分7,57% T1期。
临床怎么用
- 对于中危前列腺癌患者,需权衡剂量递增带来的生化控制获益与晚期毒性风险。
- 剂量递增可作为降低生化失败和远处转移的选择,但不应期望总生存获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Optimizing radiation therapy techniques for localized prostate cancer can affect patient outcomes. Dose escalation improves biochemical control, but no prior trials were powered to detect overall survival (OS) differences. OBJECTIVE: To determine whether radiation dose escalation to 79.2 Gy compared with 70.2 Gy would improve OS and other outcomes in prostate cancer. DESIGN, SETTING, AND PARTICIPANTS: The NRG Oncology/RTOG 0126 randomized clinical trial randomized 1532 patients from 104 North American Radiation Therapy Oncology Group institutions March 2002 through August 2008. Men with stage cT1b to T2b, Gleason score 2 to 6, and prostate-specific antigen (PSA) level of 10 or greater and less than 20 or Gleason score of 7 and PSA less than 15 received 3-dimensional conformal radiation therapy or intensity-modulated radiation therapy to 79.2 Gy in 44 fractions or 70.2 Gy in 39 fractions. MAIN OUTCOMES AND MEASURES: Time to OS measured from randomization to death due to any cause. American Society for Therapeutic Radiology and Oncology (ASTRO)/Phoenix definitions were used for biochemical failure. Acute (≤90 days of treatment start) and late radiation therapy toxic effects (>90 days) were graded using the National Cancer Institute Common Toxicity Criteria, version 2.0, and the RTOG/European Organisation for the Research and Treatment of Cancer Late Radiation Morbidity Scoring Scheme, respectively. RESULTS: With a median follow-up of 8.4 (range, 0.02-13.0) years in 1499 patients (median [range] age, 71 [33-87] years; 70% had PSA <10 ng/mL, 84% Gleason score of 7, 57% T1 disease), there was no difference in OS between the 751 men in the 79.2-Gy arm and the 748 men in the 70.2-Gy arm. The 8-year rates of OS were 76% with 79.2 Gy and 75% with 70.2 Gy (hazard ratio [HR], 1.00; 95% CI, 0.83-1.20; P = .98). The 8-year cumulative rates of distant metastases were 4% for the 79.2-Gy arm and 6% for the 70.2-Gy arm (HR, 0.65; 95% CI, 0.42-1.01; P = .05). The ASTRO and Phoenix biochemical failure rates at 5 and 8 years were 31% and 20% with 79.2 Gy and 47% and 35% with 70.2 Gy, respectively (both P < .001; ASTRO: HR, 0.59; 95% CI, 0.50-0.70; Phoenix: HR, 0.54; 95% CI, 0.44-0.65). The high-dose arm had a lower rate of salvage therapy use. The 5-year rates of late grade 2 or greater gastrointestinal and/or genitourinary toxic effects were 21% and 12% with 79.2 Gy and 15% and 7% with 70.2 Gy (P = .006 [HR, 1.39; 95% CI, 1.10-1.77] and P = .003 [HR, 1.59; 95% CI, 1.17-2.16], respectively). CONCLUSIONS AND RELEVANCE: Despite improvements in biochemical failure and distant metastases, dose escalation did not improve OS. High doses caused more late toxic effects but lower rates of salvage therapy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00033631.
引用
- Michalski JM, Moughan J, Purdy J, et al. Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial. JAMA Oncol. 2018. PMID: 29543933. doi:10.1001/jamaoncol.2018.0039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。